Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

1.

Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro a brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?

Stienen S, Salah K, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Tijssen JP, Pinto YM, Kok WE.

Eur J Heart Fail. 2015 Jul 29. doi: 10.1002/ejhf.320. [Epub ahead of print]

PMID:
26222618
2.

N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment.

Stienen S, Salah K, Dickhoff C, Carubelli V, Metra M, Magrini L, Di Somma S, Tijssen JP, Pinto YM, Kok WE.

J Card Fail. 2015 Jul 26. pii: S1071-9164(15)00622-3. doi: 10.1016/j.cardfail.2015.07.011. [Epub ahead of print]

PMID:
26216495
3.

Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.

Eurlings LW, Sanders-van Wijk S, van Kraaij DJ, van Kimmenade R, Meeder JG, Kamp O, van Dieijen-Visser MP, Tijssen JG, Brunner-La Rocca HP, Pinto YM.

J Card Fail. 2014 Dec;20(12):881-90. doi: 10.1016/j.cardfail.2014.08.014. Epub 2014 Aug 28.

PMID:
25175696
4.

Atlas of the clinical genetics of human dilated cardiomyopathy.

Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Müller S, Kayvanpour E, Vogel B, Sedaghat-Hamedani F, Lim WK, Zhao X, Fradkin D, Köhler D, Fischer S, Franke J, Marquart S, Barb I, Li DT, Amr A, Ehlermann P, Mereles D, Weis T, Hassel S, Kremer A, King V, Wirsz E, Isnard R, Komajda M, Serio A, Grasso M, Syrris P, Wicks E, Plagnol V, Lopes L, Gadgaard T, Eiskjær H, Jørgensen M, Garcia-Giustiniani D, Ortiz-Genga M, Crespo-Leiro MG, Deprez RH, Christiaans I, van Rijsingen IA, Wilde AA, Waldenstrom A, Bolognesi M, Bellazzi R, Mörner S, Bermejo JL, Monserrat L, Villard E, Mogensen J, Pinto YM, Charron P, Elliott P, Arbustini E, Katus HA, Meder B.

Eur Heart J. 2015 May 7;36(18):1123-35a. doi: 10.1093/eurheartj/ehu301. Epub 2014 Aug 27.

PMID:
25163546
5.

HCN4 mutations in multiple families with bradycardia and left ventricular noncompaction cardiomyopathy.

Milano A, Vermeer AM, Lodder EM, Barc J, Verkerk AO, Postma AV, van der Bilt IA, Baars MJ, van Haelst PL, Caliskan K, Hoedemaekers YM, Le Scouarnec S, Redon R, Pinto YM, Christiaans I, Wilde AA, Bezzina CR.

J Am Coll Cardiol. 2014 Aug 26;64(8):745-56. doi: 10.1016/j.jacc.2014.05.045.

6.

The microRNA-15 family inhibits the TGFβ-pathway in the heart.

Tijsen AJ, van der Made I, van den Hoogenhof MM, Wijnen WJ, van Deel ED, de Groot NE, Alekseev S, Fluiter K, Schroen B, Goumans MJ, van der Velden J, Duncker DJ, Pinto YM, Creemers EE.

Cardiovasc Res. 2014 Oct 1;104(1):61-71. doi: 10.1093/cvr/cvu184. Epub 2014 Aug 7.

PMID:
25103110
7.

Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes.

Stienen S, Salah K, Moons AH, Bakx AL, van Pol PE, Schroeder-Tanka JM, Voogel AJ, Keijer JT, Kortz RA, Dickhoff C, Meregalli PG, Tijssen JG, Pinto YM, Kok WE.

Am Heart J. 2014 Jul;168(1):30-6. doi: 10.1016/j.ahj.2014.04.008. Epub 2014 Apr 23.

PMID:
24952857
8.

Outcome in phospholamban R14del carriers: results of a large multicentre cohort study.

van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JD, Zwinderman AH, Pinto YM, Dit Deprez RH, Post JG, Tan HL, de Boer RA, Hauer RN, Christiaans I, van den Berg MP, van Tintelen JP, Wilde AA.

Circ Cardiovasc Genet. 2014 Aug;7(4):455-65. doi: 10.1161/CIRCGENETICS.113.000374. Epub 2014 Jun 8.

9.

Cardiomyocyte-specific miRNA-30c over-expression causes dilated cardiomyopathy.

Wijnen WJ, van der Made I, van den Oever S, Hiller M, de Boer BA, Picavet DI, Chatzispyrou IA, Houtkooper RH, Tijsen AJ, Hagoort J, van Veen H, Everts V, Ruijter JM, Pinto YM, Creemers EE.

PLoS One. 2014 May 2;9(5):e96290. doi: 10.1371/journal.pone.0096290. eCollection 2014.

10.

Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis.

Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, Persson H, O'Connor CM, Moertl D, Karlström P, Dahlström U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG.

Eur Heart J. 2014 Jun 14;35(23):1559-67. doi: 10.1093/eurheartj/ehu090. Epub 2014 Mar 6. Review.

11.

A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.

Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Damman P, Tijssen JG, Pinto YM.

Heart. 2014 Jan;100(2):115-25. doi: 10.1136/heartjnl-2013-303632. Epub 2013 Oct 31.

12.

The hypoxia-inducible microRNA cluster miR-199a∼214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation.

el Azzouzi H, Leptidis S, Dirkx E, Hoeks J, van Bree B, Brand K, McClellan EA, Poels E, Sluimer JC, van den Hoogenhof MM, Armand AS, Yin X, Langley S, Bourajjaj M, Olieslagers S, Krishnan J, Vooijs M, Kurihara H, Stubbs A, Pinto YM, Krek W, Mayr M, da Costa Martins PA, Schrauwen P, De Windt LJ.

Cell Metab. 2013 Sep 3;18(3):341-54. doi: 10.1016/j.cmet.2013.08.009.

13.

The LMNA mutation p.Arg321Ter associated with dilated cardiomyopathy leads to reduced expression and a skewed ratio of lamin A and lamin C proteins.

Al-Saaidi R, Rasmussen TB, Palmfeldt J, Nissen PH, Beqqali A, Hansen J, Pinto YM, Boesen T, Mogensen J, Bross P.

Exp Cell Res. 2013 Nov 15;319(19):3010-9. doi: 10.1016/j.yexcr.2013.08.024. Epub 2013 Aug 31.

PMID:
24001739
14.

Macrophage microRNA-155 promotes cardiac hypertrophy and failure.

Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schürmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B.

Circulation. 2013 Sep 24;128(13):1420-32. doi: 10.1161/CIRCULATIONAHA.112.001357. Epub 2013 Aug 16.

15.

MicroRNAs in heart failure: new targets in disease management.

Elzenaar I, Pinto YM, van Oort RJ.

Clin Pharmacol Ther. 2013 Oct;94(4):480-9. doi: 10.1038/clpt.2013.138. Epub 2013 Jul 12. Review.

PMID:
23852395
16.

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d. doi: 10.1093/eurheartj/eht210. Epub 2013 Jul 3.

17.

The therapeutic potential of miRNAs in cardiac fibrosis: where do we stand?

Wijnen WJ, Pinto YM, Creemers EE.

J Cardiovasc Transl Res. 2013 Dec;6(6):899-908. doi: 10.1007/s12265-013-9483-y. Epub 2013 Jul 3. Review.

PMID:
23821466
18.

Long QT syndrome: beyond the causal mutation.

Amin AS, Pinto YM, Wilde AA.

J Physiol. 2013 Sep 1;591(Pt 17):4125-39. doi: 10.1113/jphysiol.2013.254920. Epub 2013 Jun 10. Review.

19.

Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience.

van Spaendonck-Zwarts KY, van Rijsingen IA, van den Berg MP, Lekanne Deprez RH, Post JG, van Mil AM, Asselbergs FW, Christiaans I, van Langen IM, Wilde AA, de Boer RA, Jongbloed JD, Pinto YM, van Tintelen JP.

Eur J Heart Fail. 2013 Jun;15(6):628-36. doi: 10.1093/eurjhf/hft013. Epub 2013 Jan 24.

20.

Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers.

van Rijsingen IA, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP, Grasso M, Serio A, Jenkins S, Rowland C, Richard P, Wilde AA, Perrot A, Pankuweit S, Zwinderman AH, Charron P, Christiaans I, Pinto YM.

Eur J Heart Fail. 2013 Apr;15(4):376-84. doi: 10.1093/eurjhf/hfs191. Epub 2012 Nov 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk